ArticleVaccine2022

Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.

Yester F Janssen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.